-
Most cases of thrombocytopenia seen are expected. Patients are known to have hematological disease or are receiving chemotherapy. At times, however, the physician is confronted with an unexpected laboratory finding in an asymptomatic patient, or with a patient who is bleeding. The challenge, as usual, is to determine the need for acute treatment and the appropriate disposition.
-
Stop smoking drug Chantix rates stronger warning from FDA; Type 2 diabetes surgery on the way?; Vytorin study inconclusive; Influenza A virus found resistant to Tamiflu; FDA actions.
-
BOSTON How often do you hear one of the world's most renowned and veteran physicians describe the state of knowledge in his own subspecialty as "overwhelmingly ignorant" especially if that physician is the organizer of an outstanding annual conference focused on that subspecialty?
-
Ablation Frontiers (Carlsbad, California) reported receiving FDA approval to extend U.S. enrollment in its clinical trial for interventional treatment of chronic AF.
-
FORT LAUDERDALE, Florida The field of cardiothoracic surgery is clearly in transition not a new development but one heightened by a variety of pressures, professional, technological, political and economic. This assertion was highlighted in a variety of ways at the organizations annual meeting here in late January.
-
Cytori Therapeutics (San Diego) reported receiving its first orders from Europe and Asia for Celution 800 Systems. Eleven Celution 800 Systems and related CT-805 single-use consumables were ordered by Cytori's distributors MBA Grupo, which covers Spain, Italy, and Portugal, and Astrea International, which covers Singapore. Cytori says the first devices are to be delivered this quarter.
-
Heart drugs aren't all that controversial, but the approval of the heart failure drug BiDil raised some interesting questions. And its future is currently in doubt.
-
-
diaDexus (San Francisco) has received FDA clearance for a new automated version of its PLAC Test.
-
The American Heart Association (AHA; Dallas) recently reported that U.S. deaths from heart disease and stroke dropped about 25% from 1999 to 2005, five years ahead of goals.
